The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin

PharmacoEconomics

Volumn 14, Issue 1, 1998, Pages 59-70

  Koren, Michael J ^a   Smith, Dean G ^b   Hunninghake, Donald B ^c   Davidson, Michael H ^d   McKenney, James M ^e   Weiss, Stuart R ^f   Schrott, Helmut G ^g   Henley Jr , Robert W ^h   Tresh, Perry ⁱ   McLain, Richard W ⁱ   Bakker Arkema, Rebecca G ⁱ   Black, Donald M ⁱ  

^a Jacksonville Center for Clinical Research   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d RADIANT RESEARCH   (United States)

^e National Clinical Research Inc   (United States)

^f S Diego Endocr and Medical Clinic   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h Virginia Cardiovascular Specialists   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; EDUCATION PROGRAM; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; COST-BENEFIT ANALYSIS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEALTH POLICY; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LOVASTATIN; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; UNITED STATES;

EID: 7344240413     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814010-00006     Document Type: Article

References (31)

1. Summary of the second report of the National Cholesterol Education Program (NCHP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
3. Shepherd J, Cobbe SM, Ford I, West of Scotland Coronary Prevention Study Group, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20): 1301-7
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335 (14): 1001-9
5. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass suryery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55
6. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 1987; 257 (16): 2176-80
7. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916-24
8. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
9. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145-51
10. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6
11. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82
12. Zocor. Physicians desk reference. 49th ed. Montvale (NJ): Medical Economics Co., 1995: 1655-8
13. Mevacor. Physicians desk reference. 49th ed. Montvale (NJ): Medical Economics Co., 1995: 1584-8
14. Lescol. Physicians desk reference. 49th ed. Montvale (NJ): Medical Economics Co., 1995: 2165-8
15. Remmell PS, Gorder DD, Hall Y, et al. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). I: use of a dietary monitoring tool. JAMA 1980; 76: 351-6
16. Freidewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of a centrifuge. Clin Chem 1972; 18: 449-502
17. Lipid and lipoprotein analysis. In: The Laboratory Methods Committee, editors. Manual of laboratory operations: LRC program report (NIH). Vol. I. Bethesda (MD): US Department of Health. Education, and Welfare, 1974: 75-628
18. Practice Management Information Corporation (PMIC). Physician fees: a comprehensive guide for fee schedule review and management. Los Angeles: PMIC, 1996
19. Drug topics red book. Montvale (NJ): Medical Economic Company Inc., 1996
20. Agramowitz M, editor. Atorvastatin: a new lipid-lowering drug. Med Lett Drugs Ther 1997; 39: 29-31
21. Lawless JF. Statistical models and methods for lifetime data. New York: Wiley, 1982
22. Montague TJ, Tsuyuki RT, Burton JR, et al. Prevention and regressions of coronary atherosclerosis: is it safe and efficacious therapy? Chest 1994; 105: 718-26
23. American Heart Association. Heart and stroke facts [statistical supplement]. Dallas (TX): American Heart Association, 1996
24. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the national health and nutrition examination surveys. JAMA 1943; 269: 3002-8
25. Giles WH, Anda RE, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians. JAMA 1993; 269: 1133-8
26. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93 (10): 1796-802
27. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17 (7): 1001-7
28. Reckless JPD. The 4S Study and its pharmacoeconomic implications. Pharmacoeconomics 1996; 9 (2): 101-5
29. Hamilton VH, Racicot FE, Zowall H, et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA 1995; 273 (13): 1032-8
30. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patinets with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443-8
31. Ashraf T, Hay JW, Pitt B. Cost-Effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78 (4): 409-14